

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number
WO 2004/022696 A2

- (51) International Patent Classification⁷: **C12N**
- (21) International Application Number:
PCT/IB2003/004506
- (22) International Filing Date:
5 September 2003 (05.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/408,566 6 September 2002 (06.09.2002) US
60/433,715 16 December 2002 (16.12.2002) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier applications:
US 60/408,566 (CIP)
Filed on 6 September 2002 (06.09.2002)
US 60/433,715 (CIP)
Filed on 16 December 2002 (16.12.2002)
- (71) Applicant (for all designated States except US): **ISOTIS SA** [CH/CH]; 18-20 Avenue de Sévelin, CH-1004 Lausanne (CH).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **RONFARD, Vincent** [FR/US]; 67 Cherry Place, Newton, MA 02465 (US).
- (74) Agents: **PRINS, A., W. et al.**; c/o Vereenigde, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **FIBRIN CELL SUPPORTS AND METHODS OF USE THEREOF**

(57) Abstract: The present invention relates to fibrin cell supports for cell cultures formed by the mixture of plasma proteins including fibrinogen and thrombin. The fibrin cell supports are preferably used for preparing a culture of cells such as keratinocytes, recovering the culture in the form of a reconstituted tissue, and transporting same. The reconstituted tissue is particularly suitable for use as a skin graft.

WO 2004/022696 A2

FIBRIN CELL SUPPORTS AND METHODS OF USE THEREOF

FIELD OF THE INVENTION

5 The present invention relates to a fibrin cell support for cell cultures, containing a coagulated mixture of plasma proteins including fibrinogen and thrombin; its use in the preparation of cell cultures; its transport and transplantation in the form of an isolated cell, colonies of cells, or a reconstituted epithelia; and its use for therapeutic purposes.

BACKGROUND OF THE INVENTION

10 The reconstitution of a living skin similar to the human skin from a few cells obtained from a biopsy, or of a simplified skin performing the physiological functions of a normal skin, is being studied extensively with the aim of replacing skin damaged by disease (hemangiomas, keloids, hypertrophic scarring, bullous pemphigoid, viral or bacterial
15 infection, or acne), by trauma such as major burns, by an acute wound (such as plastic surgery or removal of a tumor mass) or by chronic wounds (*e.g.*, ulcers).

The skin is a complex organ composed of three juxtaposed tissues: the epidermis, 85% of which is constituted by keratinocytes, which form the impermeable layer that isolates the body from the outside environment; the dermis, which comprises cells, including
20 fibroblasts, separated by a connective tissue composed mainly of collagen; and the hypoderma, which includes the cells dedicated to storing fats. Artificial reconstitution of such a complex organ thus poses numerous problems. Both dermis and epidermis have been partially reconstituted *in vitro*. (*See Bell et al.*, Proc. Natl. Acad. Sci. 76:1979-1274).

Starting with skin biopsies, fibroblasts have been successfully established in cultures,
25 first in monolayers, then, after a number of passages, by dispersing these cells in culture medium containing collagen (extracted from rat's tail tendons), the latter forming a gel and permitting three-dimensional cultures. In such cultures, the fibroblasts interact with the collagen matrix, organizing and contracting it, as occurs in a normal dermis. This tissue,

reconstituted *in vitro*, is known as a "dermal equivalent". After a few weeks' growth, the mechanical qualities of the equivalent dermis allow it to be used for grafting onto a patient or injured person. It does not appear to be rejected by its host. However, this equivalent dermis is merely a temporary dressing as it cannot restore the skin's cutaneous barrier function.

Furthermore, a method and a culture medium enabling keratinocytes to be grown for long periods has been developed previously. (See Green et al. (1979) Proc. Natl. Acad. Sci. 76:5665-8). This method includes the step of inoculating the keratinocytes dispersed with trypsin on a pre-established monolayer of fibroblasts, in particular 3T3 cells, which have been lethally irradiated and which serve as a nutritive layer and as a matrix. An epidermal layer develops very rapidly to form a tissue having a thickness of 3 to 5 cells, and it can be grafted onto a patient and continue to differentiate *in situ*. This technique has been used to treat patients suffering from severe burns. (See Gallico et al. (1984) New England J. Med. 311:448).

Using the technique of Green et al., it is possible to obtain, from a biopsy of two square centimeters, an epidermis of one square meter in the space of three weeks.

However, recovery of the reconstituted tissue in order to make a graft therefrom still poses a number of technical problems. For example, it is necessary to detach the multilayered epithelium from the culture dish using an enzyme treatment without dissociating the cells. During this procedure, a retraction of the cell layer, and, hence, a loss of a certain percentage of the surface area of the graft, is observed. Moreover, once the reconstituted tissue has been detached, it has to be fastened to a support that enables it to be transported and grafted onto the patient. Typically, an adhesive-treated gauze dressing is generally used. These manipulations are both delicate and time consuming, which jeopardizes the quality of the graftable epithelium.

Thus, it would thus be highly beneficial to have at one's disposal novel fibrin cell supports that can be resorbed by the patient who has received the graft and that simplify the handling and preserving the quality of the cultured epithelium. In addition, to ensure their availability, such supports or their constituents should lend themselves to preparation and packaging in accordance with industrial processes.

SUMMARY OF THE INVENTION

In one aspect, the invention involves a fibrin cell support for cell cultures including thrombin and fibrinogen, where the concentration of thrombin is between about 0.5 U/ml

and about 2.5 U/ml. Generally, the concentration of fibrinogen is between about 10 and about 250 mg/ml. In some embodiments of the present invention, the fibrin cell support includes a protease inhibitor (*i.e.*, an anti-protease) such as aprotinin or a synthetic protease inhibitor (*e.g.*, tranexamic acid), or other molecules including polypeptide growth factors, cytokines, enzymes, hormones, antibiotics, antimycotics, or a combination of two or more of these molecules. In other embodiments of the present invention, the fibrin cell support further includes one or more cells, *e.g.*, keratinocytes or other epithelial cells. In some embodiments, the thrombin is calcic thrombin.

In another aspect, the present invention provides a method of preparing a fibrin cell support, including the steps of mixing equivalent volumes of a first solution comprising fibrinogen and a second solution comprising thrombin; and distributing the mixture onto a surface, such that a fibrin cell support is formed on the surface. In certain embodiments of the present invention, this method further provides contacting with the fibrin cell support one or more cells, *e.g.*, keratinocytes or other epithelial cells.

In yet another aspect, the present invention provides a method of using a fibrin cell support, including the steps of contacting one or more cells with a fibrin cell support to form a skin replacement tissue, where the support includes thrombin and fibrinogen; and recovering, transporting and applying the skin replacement tissue as a graft. The cells may be located on the surface of the fibrin cell support or integrated within the fibrin cell support.

In a further aspect, the present invention provides a method of using a skin replacement tissue, by contacting one or more cells with a solution comprising fibrinogen and thrombin, to form a skin replacement tissue and transporting the skin replacement tissue to a patient in need thereof.

In another aspect, the present invention provides a method for decreasing the probability of mechanical damage to the fibrin cell support during transport prior to transplantation.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the

present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description and claims.

5

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is a series of photographs that demonstrate the increased *in vitro* attachment of epithelia on a fibrin support located on the surface of an artificial membrane.

Figure 2 is a series of photographs that demonstrate the increased *in vivo* acceptance
10 of a graft that includes a fibrin cell support and cultured epithelia.

Figure 3 is a graph that demonstrates the reduced wound contraction of an epithelial cell graft when cultured with a fibrin cell support.

DETAILED DESCRIPTION OF THE INVENTION

15 The present invention provides novel fibrin cell supports useful for culturing cells. These supports are formed by the coagulation of plasma proteins including fibrinogen in the presence of thrombin. This coagulation is chiefly the result of the formation of a polymerized fibrin network, which imitates the formation of a blood clot. Thrombin converts fibrinogen to fibrin by enzymatic cleavage, and also converts protransglutaminase (factor XIII) to an active transglutaminase (factor XIIIa). Calcium accelerates the proteolytic
20 activity of thrombin. To form a support suitable for the preparation of cell cultures, coagulation is carried out under conditions that are conducive to the formation of a film, and more particularly, in cell culture flasks or dishes.

One aspect of the present invention involves a fibrin cell support useful for culturing
25 cells. This support is generated by combining a solution of a plasma protein such as fibrinogen with a solution of calcic thrombin such that a fibrin matrix forms, on which cells can be supported and cultured. The term "calcic thrombin" as used herein includes thrombin in the presence of calcium. For example, calcic thrombin includes a solution containing thrombin and any concentration of calcium. Fibrinogen can also be contacted with thrombin
30 in the absence of calcium.

Plasma proteins such as fibrinogen can be obtained from human plasma, (*e.g.*, obtained from blood donors) or can be recombinant. If in solid form (such as freeze-dried or lyophilized), the fibrinogen must be reconstituted, *e.g.*, in an isotonic solution. In some embodiments of the present invention, the isotonic solution is isotonic sodium chloride

containing calcium chloride. The concentration of sodium chloride may be in the range of about 0.5% to about 5.0%, preferably in the range of about 1.0% to about 3.0%, and the concentration of calcium chloride may be in the range of about 0.5mM to about 5mM, preferably in the range of about 1mM to about 2mM. The isotonic solution may further

5 comprise one or more protease inhibitors, *e.g.*, a polyvalent protease inhibitor such as aprotinin, provided in a concentration range of about 1,000-10,000 KIU/ml (kallikrein inhibitor units/ml), preferably about 3000 KIU/ml. Alternatively, such protease inhibitor(s) in solution may be added directly to the fibrinogen to reconstitute the protein. The concentration of fibrinogen is usually about 1-1000 mg/ml, preferably 10-250 mg/ml, more
10 preferably 50-150 mg/ml, and most preferably 60 mg/ml. The fibrinogen solution may additionally contain other plasma proteins or polypeptides including, but not limited to, fibronectin, Factor VIII and Factor XIII.

Likewise, the thrombin may also be derived from natural sources or may be recombinant or synthetic. If in solid form, thrombin can be reconstituted in an isotonic
15 solution containing calcium, *e.g.*, 1.1% NaCl containing 1 mM calcium chloride. The concentration of the thrombin solution is usually about 0.1-10 U/ml, preferably 0.5-5.0 U/ml, even more preferably 1-3 U/ml and most preferably 2.5 U/ml. Units of thrombin refer to the activity standard as defined by the NIH standard. One NIH unit corresponds to 1.15 International Units. (*See, e.g.*, Gaffney et al. (1995) J. Thromb. Haemost. 74:900-3).
20 Thrombin may also be combined with fibrinogen in the absence of calcium. However, those skilled in the art will recognize that the presence of calcium accelerates the proteolytic activity of thrombin.

The fibrinogen solution and the thrombin solution are combined (usually in equal volumes) and are distributed to a vessel, such as a tissue culture dish, before clotting occurs.
25 Once clotting occurs, a fibrin cell support or matrix is formed. Alternatively, the two solutions may be injected into a vessel simultaneously using two syringes interconnected by a mixing coupling. Generally, the fibrin matrix formed by the combination of the calcic thrombin and the fibrinogen solutions will be transparent. The volume of the solution containing fibrinogen and thrombin used is dependent upon the thickness of the fibrin cell
30 support desired. Typically, about 2.5 ml of each solution is used for approximately every 100cm² of surface.

Those skilled in the art will recognize that other polypeptides or molecules (*e.g.*, growth factors or cytokines such as EGF, VEGF, PDGF, NGF, and TGF- β ; healing agents; enzymes such as matrix-degrading enzymes and matrix-degrading enzyme inhibitors (*e.g.*,

TIMPs); antibiotics; and/or and antimycotics) may be added to the fibrinogen solution and/or the thrombin solution prior to, concomitant with, or following the mixing of the calcic thrombin and the fibrinogen components. Moreover, the plasma transglutaminase factor XIIIa may be added to the fibrinogen solution, the thrombin solution, the mixture, or to the
5 fibrin cell support in order to covalently crosslink the resulting fibrin cell support.

The fibrin cell support according to the invention is advantageous when preparing cell cultures, particularly keratinocyte cultures, such as human keratinocyte cultures. These cell cultures can be either primary cultures derived from skin biopsies obtained from a patient that have undergone between 1 and 6 or more passages in 1/15 to 1/20 dilutions, or
10 cells preserved in the form of banks in liquid nitrogen. Cells may be cultured in the presence of a feeder cell layer, such as a layer of lethally-irradiated human fibroblasts (*See Limat et al.*, 1986 *J Invest Dermatol.* 1986 Oct;87(4):485-8).

In some embodiments of the present invention, cells such as keratinocytes are grown to confluence, trypsinized, suspended in an appropriate culture medium, and replated on the
15 fibrin cell support. Cells may also be plated on the fibrin cell support at a subconfluent density and allowed to reach confluence in culture on the fibrin cell support. Cells may also be added to the mixture of thrombin and fibrinogen prior to coagulation, such that the cells are embedded within the fibrin cell support.

The invention includes any mammalian or non-mammalian mammalian cell type that
20 is capable of being maintained under cell culture conditions, and preferably of *in vitro* expansion in number and of subsequent integration into a reconstituted epithelium. In some embodiments, the cells are isolated from and re-introduced into the same animal (autologous cells, *i.e.*, cells obtained from the intended recipient), thus avoiding the risk of immune rejection and disease transmission. In other embodiments, the cells are isolated from
25 allogeneic embryonic or neonatal tissue that is inherently less immunogenic than adult tissue. In still other embodiments, so-called immunologically neutral allogeneic cells are used. Immunologically neutral allogeneic cells are allogeneic cells of either fetal or adult origin which themselves have been genetically modified to eliminate the synthesis and/or expression of the cell surface antigens which are responsible for the self/non-self recognition
30 by the immune system of the recipient. Such antigens fall chiefly within, but are not limited to, the major histocompatibility complex ("MHC"), Classes I and II.

Isolated cells can be obtained from humans or other mammals (*e.g.*, rodents, primates, cows, or pigs). In certain embodiments, these cells can be derived from skin or other organs such as eyes, heart, brain or spinal cord, liver, lung, kidney, pancreas, bladder,

bone marrow, spleen, muscle, intestine, or stomach. In other embodiments, these cells can be stem cells which can be differentiated into a desired cell type in culture.

In particular embodiments of the invention, the isolated cells are keratinocytes, *e.g.*, epidermal keratinocytes; oral and gastrointestinal mucosal epithelia; urinary tract epithelia; 5 corneal epithelial cells; corneal epithelial stem cells; as well as epithelia derived from other organ systems, skeletal joint synovium, periosteum, bone, perichondrium, and cartilage; fibroblasts; muscle cells (*e.g.* skeletal, smooth, or cardiac muscle cells); endothelial cells; pericardial cells; dural cells; cells of the meninges; keratinocyte precursor cells; keratinocyte stem cells (*e.g.*, NIKS™); endothelial cells; pericytes; glial cells; neural cells; amniotic and 10 placental membrane cells; stem cells; and serosal cells (*e.g.*, serosal cells lining body cavities). The cells of the present invention may also include recombinant or genetically modified cells.

Those skilled in the art will recognize that the use of the fibrin cell support according to the invention can be adapted in multiple ways. For example, according to one method of 15 use, the fibrin cell support is prepared in the form of a film, by mixing its two constituents (thrombin, calcic thrombin and fibrinogen) in a culture dish. A suspension of cells is then seeded on this film, in an appropriate culture medium. When the cell culture has become confluent or semi-confluent, it forms a replacement tissue that can be recovered directly as a graft, which can be detached using forceps and transported from the culture dish to the 20 patient. It can be applied to the wound as is, without any need for a temporary support, such as gauze. This method leads to a considerable saving in working time as well as a 100% recovery of the tissue grown.

According to another method of using the fibrin cell support of the invention, the two constituents of the support are mixed with a cell suspension in such a way as to integrate the 25 cells within the film that is subsequently formed. According to this method, the two constituents can be mixed with the cell suspension in a culture dish and then used as a graft, as described above. This method may also be carried out directly on a wound site on a patient, which has been prepared to receive a graft, by spraying a mixture of the fibrin cell support and the cells onto the wound using a vector gas (nitrogen) at a pressure of 2 to 2.5 30 bars, or by applying a paste to the wound.

According to a further method of using the fibrin cell support according to the invention, the two constituents of the support are mixed to form a viscous cell paste to adhere to a wound. Preferably, the resulting paste is both biodegradable and biocompatible. The paste may be applied to the wound as needed, for example, once weekly. Application of

the cell paste according to this embodiment facilitates the induction of granulation tissue and the stimulation of wound closure.

According to yet another method of using the support according to the invention, the two constituents are mixed on a layer of cells that has been pre-established in a culture dish.

5 This is done in such a way that the cells become coated with the film that is subsequently formed. In this method the cells can be detached and transported in order to be applied to a wound as a graft.

In certain embodiments of the invention, the support further contains one or more disinfectants, preferably methylene blue, and/or one or more drugs selected from antibiotics, fibrinolytic agents, and biological response modifiers such as cytokines and wound repair promoters. Preferably, these compounds are included in an amount up to 1% by weight in terms of the total dry weight of fibrin plus thrombin. Examples of suitable fibrinolytic agents include t-PA, μ -PA, streptokinase, staphylokinase, plasminogen and the like, which promote fibrinolysis and, thus, can be used to control the rate of the degradation of the fibrin film *in vivo*. As used herein, the term "biological response modifiers" refers to substances that are involved in modifying a biological response, such as wound repair, in a manner which enhances a desired therapeutic effect of the fibrin cell support. Examples of suitable biological response modifiers include cytokines, growth factors, wound repair promoters, and the like.

20 Additionally, it may be necessary to deliver the fibrin cell support from the facility where it is generated to a facility where it is used. Therefore a system is needed for the transport of the fibrin cell supports of the invention. A first system involves contacting the fibrin cell support with a cylindrical inner carrier. For example, the fibrin cell support can be rolled around the inner carrier, which can be solid or hollow, such as a plastic tube. The fibrin cell support and the inner carrier are then placed in a hollow outer carrier which has an inner diameter larger than the outer diameter of the inner carrier. The space between the fibrin cell support and the inner wall of the outer carrier is then filled with cell media or other suitable material and the outer carrier is sealed so as to maintain a sterile environment.

A second transport system involves contacting the fibrin cell support with an essentially flat or planar carrier (*e.g.*, a natural or synthetic material such as a polyester membrane). The carrier has two sheets operably linked to each other. The carrier can also be an envelope into which the fibrin cell support and suitable cell culture media are inserted. The fibrin cell support is adhered to the carrier with the cells in contact with the carrier. Alternatively, the fibrin cell support is adhered to the carrier with the cells not in contact

with the carrier. Suitable carriers may consist of a synthetic membrane made from one or more of the following materials (polyester, PTFE or polyurethane); from one or more biodegradable polymers (*e.g.*, hyaluronic acid, polylactic acid or collagen); or a silicone or vaseline gauze dressing, or any other material suitable for wound dressing.

- 5 The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.

EXAMPLES

Example 1: Preparation of a fibrin cell support for cell cultures

- 10 A fibrin cell support for cell cultures is prepared by mixing a solution containing fibrinogen and a solution containing calcic thrombin.

- Lyophilized fibrinogen (375-575 milligrams) is reconstituted with 5 ml of aprotinin (3,000 KIU/ml; kallikrein inhibitor units/ml) then combined with 5 ml of 2.2% NaCl containing 2mM calcium chloride. Lyophilized thrombin (225 to 275 milligrams;
15 approximately 2500 International Units) is diluted in 1.1% NaCl containing 1mM calcium chloride to a final concentration of 0.225 to 0.275 milligrams or 2.5IU. The solubilized fibrinogen and solubilized thrombin are mixed in a 1:1 ratio and dispensed into a cell culture dish or flask (2.5 mls of the fibrinogen-thrombin mixture per 100 cm² of culture dish surface) to form a fibrin cell support. The fibrin cell support is then covered in cell culture
20 medium.

Example 2: Preparing a keratinocyte culture on the fibrin cell support

- Human keratinocytes originating from a skin biopsy are cultured in the presence of lethally-irradiated or mitomycin C-treated human fibroblasts, or lethally-irradiated or
25 mitomycin C-treated murine feeder cells. (*See* Limat et al. (1986) J Invest Dermatol. 87(4):485-8; Green et al. (1979) Proc. Natl. Aced. Sci. 76:5665).

- A layer of confluent keratinocytes is trypsinized, replaced in suspension in culture medium and seeded at subconfluent density (*e.g.*, in a 1/10 dilution) on a tissue culture dish covered with the fibrin cell support prepared as described in Example 1. The keratinocytes
30 are then allowed to reach confluence, at which point the resulting keratinocyte graft can be used in therapeutic methods. The fibrin cell support of this invention stands up well to handling and does not retract at the time of detachment, which makes it possible to recover 100% of the surface area of the cell layer of the culture.

In another embodiment the keratinocytes of the fibrin cell support are at sub-confluent concentrations. For example, the keratinocytes may be in two or more colonies, each colony containing between about 4 and about 1,000 cells.

5 The keratinocyte graft can be applied to a patient in need thereof in a method such that the fibrin cell support contacts the patient, or alternatively, the keratinocyte cell layer contacts the patient.

Example 3: Recovery of a pre-established cell layer using the fibrin cell support

10 Keratinocytes are inoculated according to Green's conventional method, in a Petri dish covered with a layer of lethally irradiated fibroblasts. (See Green et al. (1979) Proc. Natl. Acad. Sci. 76:5665). When keratinocytes are confluent and formed of several layers of cells, the culture medium is removed, an EDTA solution is added for 1 hour 30 minutes. This is followed by washing twice with PBS. The fibrin cell support prepared as described in

15 Upon coagulation of the fibrin cell support, it can be detached mechanically and used as a graft, as demonstrated in Example 2.

Example 4: Incorporation of keratinocytes into the fibrin cell support

20 Keratinocytes can be embedded within the fibrin cell support by any of several methods. In a first method, a syringe of solubilized fibrinogen and a syringe of solubilized thrombin containing the keratinocytes in suspension are prepared. These keratinocytes may be taken from a fresh, trypsinized culture or from a bank of cells preserved in liquid nitrogen. The two syringes are interconnected by means of a mixing coupling and the resulting fibrin cell support containing the cells is sprayed onto a tissue culture dish (or onto

25 a wound prepared to receive the graft). In this method, the cells are held within the fibrin cell support during its coagulation. The spraying can be carried out using a vector gas (e.g., nitrogen at a pressure of 2 to 2.5 bars) or any other method known to those skilled in the art. This spraying does not damage the cells or denature the polypeptides, and the cell layer can be observed to reform in culture. These cells should thus multiply normally when the

30 mixture is sprayed, in a very thin layer, directly onto a wound.

In a second method, the solubilized fibrinogen and solubilized thrombin are mixed in a 1:1 ratio, combined with a solution containing keratinocytes, and dispensed into a cell culture dish or flask (2.5 mls of the fibrinogen-thrombin mixture per 100 cm² of culture dish surface) to form a fibrin cell support containing keratinocytes.

Example 5. Artificial dermis and fibrin epithelium combination

The fibrin cell support of the present invention is useful for the early and temporary coverage of acute wounds that are currently treated by the application of an acellular artificial skin (e.g., INTEGRA[®], developed by Integra LifeSciences, Inc, Plainsboro, NJ). Generally, when an acellular artificial skin is applied onto the wound bed of a patient in need thereof, 3 to 5 weeks of time are required for the patient's own cells to invade the matrix and create a new dermis. Thereafter, an epidermal autograft is necessary to achieve permanent wound closure. Conventional cultured epithelium autografts have been partially unsuccessful to provide that coverage, because of lack of epithelial anchorage onto the INTEGRA[®] matrix. The use of the fibrin cell support of the present invention greatly improves the epithelial anchorage and success of the skin graft.

Keratinocytes were cultured according to the method of Rheinwald & Green modified by Limat and colleagues (Gallico et al. 1984, Limat et al. 1986). Human keratinocytes were cultivated on the top of the fibrin matrix in the presence of aprotinin. When the culture reached confluence, the epithelial sheet along with the fibrin was applied on INTEGRA[®]. A control culture (CEA control) was treated with Dispase upon reaching confluence in order to detach the epithelial sheet from the bottom of the dish. (See Green et al., 1979). Then the epithelial sheet was lifted off the plate using a silicone membrane, and applied onto the INTEGRA[®].

In vitro grafting and culture: INTEGRA[®] pieces (0.8 x 0.8cm) were seeded with human dermal fibroblasts and cultured for 2 weeks. They were then placed on cell culture inserts so that they were fed from the basolateral surface. Control epithelium (CEA) and fibrin epithelium were then placed on the INTEGRA[®] and covered with a silicone membrane.

In vivo grafting: surgery on mice proceeded according to standard guidelines of animal care and approved by veterinary authorities. Athymic mice (NIH Swiss nude) approximately 6-8 weeks in age (24-32 g in weight) were anaesthetized. A full thickness skin wound approximately 2.2 cm² was made on the central dorsum of each animal and covered with INTEGRA[®]. Then, Vaseline gauze and adhesive bandages were applied onto the graft. Dressings were changed every week. CEA control and fibrin epithelium were grafted 3 weeks later. One week later, the silicone membrane was removed but the dressing kept. Another week later, all remaining dressing was removed and the grafts were left uncovered. Biopsies were harvested from 15 and 21 days after grafting.

Histology: Biopsies were fixed in buffered formalin (5%) and embedded in paraffin wax. five μm sections were stained with haematoxylin-Eosin. Human involucrin (Biomedical Technology Inc., Stoughton, MA) was used to identify human keratinocytes from mouse tissue. These studies demonstrate that (1) 100 % of the epithelium grown in the presence of the fibrin sheet attached to the INTEGRA[®] and were able to develop a stratified epithelium after 2 weeks of culture compare to only 50 % for the control epithelium; (2) retraction of the grafting area was significantly lower 2 weeks after grafting ($p < 0.05$) when the epithelium was grown in the presence of the fibrin sheet compared to the CEA control epithelium; and (3) 75 % of the mice grafted with fibrin epithelium showed the presence of a differentiated human epidermis 21 days after grafting, while such an epidermis was absent in all the animals of the control group (as revealed by the absence of a specific human cell marker). The use of a fibrin matrix also greatly improved cell adhesion, epidermis development and graft take onto INTEGRA[®].

Results:

In vitro attachment of epithelia using a fibrin cell support

Figure 1 shows the evaluation of the quality of the epithelium applied on the top of INTEGRA[®] after 2 days of culture: (A) CEA control on INTEGRA[®] without fibroblasts, (B) CEA control on INTEGRA[®] with fibroblasts, (C) fibrin epithelium on INTEGRA[®] without fibroblasts, (D) fibrin epithelium on INTEGRA[®] with fibroblasts. A well-organized epithelium is obtained with fibrin epithelium (C, D) when compared to the control CEA (A, B).

Histological cross-sections of the CEA control: showed that: (1) attachment areas were far more numerous when INTEGRA[®] was populated with cells as compared to unpopulated INTEGRA[®] matrices and (2) in both the unpopulated INTEGRA[®] and the INTEGRA[®] populated with cells, the edges of the epithelium were not attached and were often folded. Until the second day of culture, many areas of the CEA control showed dying cells with apoptotic nucleus and also differentiating cells so unable to further divide. This indicates that the cell take yield for the CEA control on INTEGRA[®] was poor (Figure 1).

In contrast, the main attached areas of the fibrin epithelium were at the edges of the grafts (See Figure 1 C, D). The keratinocytes migrated from the fibrin layer to the INTEGRA[®], forming a bond between the fibrin epithelium and the INTEGRA[®]. The same attachment feature was observed both for fibroblast populated and unpopulated INTEGRA[®] matrices, creating sufficient attachment strength for the fibrin epithelium to remain in place

even when the silicone sheet covering the grafted fibrin epithelium was removed at day 7 of the culture. Close junctions were seen between fibrin layer and fibroblasts in the fibroblasts populated matrices, suggesting the formation of a normal stratified skin architecture. The epithelial layer was made of normal, proliferating cells with round nuclei and no intercellular spaces or intracellular vacuoles, as were seen for the control epithelia. Thus, the fibrin layer provides a suitable environment for the keratinocytes to survive and for the epithelium to stratify. Thus, cell survival after "*in vitro* grafting" was increased in the presence of the fibrin epithelium in comparison with controls (Figure 1).

10 *In vivo* epithelial graft with a fibrin cell support

A full thickness skin wound approximately 2.2 cm² was made on the central dorsum of each nude mouse and covered with INTEGRA[®]. CEA control and fibrin epithelium were grafted 3 weeks after the implantation of INTEGRA[®]. Biopsies were harvested from 15 and 21 days after grafting. Human involucrin antibody was used to differentiate human keratinocytes from mouse tissue by immunohistological staining on histological cross-sections.

Figure 2 shows the increased success of an epithelial graft in nude mice using a fibrin cell support. Figure 2A shows INTEGRA[®] alone; Figure 2B INTEGRA[®] with CEA control; Figure 2C INTEGRA[®] with fibrin epithelium and Figures 2D-F represent the cross section of each corresponding graft (40X magnification). Substantial graft retraction occurred in the presence of INTEGRA[®] alone or INTEGRA[®] with CEA control, as compared to INTEGRA[®] with a fibrin epithelium. Graft success (or "take") occurred only when fibrin epithelium was applied onto INTEGRA[®] as shown by the presence of the human keratinocyte marker, involucrin. The hollow arrowheads in Figure 2F indicate mouse epidermis.

Human epidermis was identified at the wound site only in animals grafted with fibrin epithelium (5 out of 6 animals versus 0 out of 6 mice for CEA control (day 14 and 21 post-grafting) (Figure 2)). The retention of the epithelial graft over time was also examined. Figure 3 shows the size of the epithelial grafts in the presence or absence of a fibrin cell support on nude mice up to 40 days after grafting. As previously described, INTEGRA[®] was applied on all mice on day 0 and left undisturbed for 19 days. Then sheets of epithelium cultivated without fibrin (CEA control) or with fibrin (fibrin epithelium) were applied onto INTEGRA[®]. The size of the graft was measured with a caliper and animals were sacrificed on day 40. Less retraction occurred when fibrin epithelium was applied onto INTEGRA[®]. A lower contraction rate of the initial wound size compared to animals grafted with CEA

control or with no epithelial grafting was observed (Figure 3). Therefore, the fibrin epithelium improved graft take, as compared to the control epithelial grafting method. This is supported by the increased cell survival shown above in *in vitro* studies.

5 Example 6: Method to package the fibrin cell support containing epithelial cells

In order to facilitate the shipping and the transportation of the fibrin cell support containing epithelial cells, a fibrin cell support containing a confluent sheet of epithelium was rolled onto an inner plastic tube, and the fibrin cell support and plastic tube were inserted into an outer plastic tube. This outer tube was filed with medium, hermetically
10 sealed and kept at room temperature for 48 hours. After this time, the stored epithelium were assayed for metabolic activity and viability (MTT test). The results demonstrated that metabolic activity is similar to the control fibrin epithelium not stored in this manner.

15

OTHER EMBODIMENTS

While the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

What is claimed is:

1. A fibrin cell support for skin grafts, comprising thrombin and fibrinogen, wherein the concentration of thrombin is between about 0.5 U/ml and about 2.5 U/ml.
2. The fibrin cell support according to claim 1, wherein the concentration of fibrinogen is between about 10 and about 250 mg/ml.
3. The fibrin cell support according to claim 1, wherein the concentration of thrombin is between about 1.0 U/ml and about 1.5 U/ml.
4. The fibrin cell support according to claim 1, wherein the concentration of thrombin is about 1.25 U/ml and the concentration of fibrinogen is between about 75 and about 150 mg/ml.
5. The fibrin cell support according to claim 1, further comprising a protease inhibitor.
6. The fibrin cell support according to claim 2, further comprising a protease inhibitor.
7. The fibrin cell support according to claim 3, further comprising a protease inhibitor.
8. The fibrin cell support according to claim 4, further comprising a protease inhibitor.
9. The fibrin cell support according to claim 1, wherein said protease inhibitor is aprotinin.
10. The fibrin cell support according to claim 9, wherein the concentration of said aprotinin is between about 1,000 KIU/ml and about 10,000 KIU/ml.
11. The fibrin cell support according to claim 9, wherein the concentration of said aprotinin is about 3000 KIU/ml.
12. The fibrin cell support according to claim 1, further comprising one or more molecules selected from the group consisting of a polypeptide growth factor, a

cytokine, an enzyme, a hormone, an antibiotic, a protease inhibitor, and an antimycotic, or a combination thereof.

13. The fibrin cell support according to claim 2, further comprising one or more molecules selected from the group consisting of a polypeptide growth factor, a cytokine, an enzyme, a hormone, an antibiotic, a protease inhibitor, and an antimycotic, or a combination thereof.
14. The fibrin cell support according to claim 3, further comprising one or more molecules selected from the group consisting of a polypeptide growth factor, a cytokine, an enzyme, a hormone, an antibiotic, a protease inhibitor, and an antimycotic, or a combination thereof.
15. The fibrin cell support according to claim 1, further comprising one or more cells.
16. The fibrin cell support according to claim 2, further comprising one or more cells.
17. The fibrin cell support according to claim 3, further comprising one or more cells.
18. The fibrin cell support according to claim 4, further comprising one or more cells.
19. The fibrin cell support of claim 15, wherein said cells are keratinocytes.
20. The fibrin cell support according to claim 1, wherein the thrombin is calcic thrombin.
21. A method of preparing a fibrin cell support, comprising:
 - a) mixing equivalent volumes of a first solution comprising fibrinogen and a second solution comprising calcic thrombin, wherein the concentration of calcic thrombin is between about 1.0 U/ml and about 1.5 U/ml; and
 - b) distributing said mixture onto a surface, such that a fibrin cell support is formed on said surface.
22. The method of claim 21, further comprising contacting said fibrin cell support with one or more cells.

23. The method of claim 22, wherein said cells are epithelial cells.
24. The method of claim 23, wherein said epithelial cells are keratinocytes.
25. The method of claim 23, wherein said epithelial cells are corneal epithelial cells.
26. The method of claim 21, further comprising contacting said mixture with one or more cells prior to distributing said mixture on said surface, thereby integrating said cells into said fibrin cell support.
27. The method of claim 21, wherein said surface is a tissue culture dish or flask.
28. A method of using a fibrin cell support, comprising:
 - a) contacting one or more cells with a fibrin cell support to form a skin replacement tissue, said support comprising calcic thrombin and fibrinogen, wherein the concentration of calcic thrombin is between about 1.0 U/ml and about 1.5 U/ml; and
 - b) recovering the skin replacement tissue;
 - c) optionally transporting the skin replacement tissue; and
 - d) applying the skin replacement tissue as a graft.
29. The method according to claim 28, wherein said cells are on the surface of said fibrin cell support.
30. The method according to claim 28, wherein said cells are keratinocytes.
31. The method according to claim 28, wherein said cells are integrated within said fibrin cell support.
32. The method according to claim 28, wherein said cells are keratinocytes.

33. The method according to claim 28, wherein said cells are obtained after dispersion of a fresh cell layer.
34. The method according to claim 28, wherein said cells are obtained from a bank of cells preserved in liquid nitrogen.
35. A method of using a skin replacement tissue, comprising:
 - a) contacting one or more keratinocytes with a solution comprising fibrinogen and calcic thrombin, wherein the concentration of calcic thrombin is between about 1.0 U/ml and about 1.5 U/ml, to form a skin replacement tissue, and
 - b) optionally transporting said skin replacement tissue to a patient in need thereof.
36. The method of claim 35, wherein said solution is added to a cell layer comprising keratinocytes in a culture dish.
37. The method of claim 35, wherein said keratinocytes are obtained from a bank of cells preserved in liquid nitrogen.
38. A method of storing a fibrin cell support, comprising:
 - a) contacting a fibrin cell support with a cylindrical inner carrier;
 - b) inserting said fibrin cell support and said inner carrier in a hollow outer carrier, said outer carrier having an inner diameter larger than the outer diameter of the inner carrier;
 - c) filling the space formed between the fibrin cell support and the inner wall of the outer carrier with cell media; and sealing the outer carrier so as to maintain a sterile environment, thereby storing the fibrin cell support.
39. A method of storing a fibrin cell support, comprising:
 - a) contacting a fibrin cell support with a carrier, said carrier comprising a first and a second sheet, said first and said second sheets operably linked to each other, such that said support contacts said first sheet;

- b) filling the space formed between the fibrin cell support and said second sheet with cell media; and contacting said first and said second sheet so as to maintain a sterile environment, thereby storing the fibrin cell support.
40. The method of claim 39, whereby said fibrin support comprises one or more cells.
41. The method of claim 40, whereby said cells contact said first sheet.
42. The method of claim 41, whereby said cells do not contact said first sheet or said second sheet.

1/3




Fig. 1A




Fig. 1C




Fig. 1B




Fig. 1D

Figure 1.

BEST AVAILABLE COPY




Fig. 2A




Fig. 2D



Fig. 2B




Fig. 2E




Fig. 2C




Fig. 2F

Figure 2.

3/3




Figure 3.

TRA 1743075v2

INTERNATIONAL SEARCH REPORT

rec'd PCT/PTO 0 4 MAR 2005

10/526857

International Application No

IB 03/04506

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L27/22 A61L27/60 C12N5/00 A61L24/06 C12M1/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L C12N C12M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/25838 A (DELMOTTE YVES ; BELOT NATHALIE (BE); TASIAUX NICOLE (BE); VERMEULEN PI) 11 May 2000 (2000-05-11) claims 21,27-29,31,45	1-4, 15-24, 28-30, 32-35,37
X	US 5 474 770 A (BROLY HERVE ET AL) 12 December 1995 (1995-12-12) column 2, line 4 - line 23 column 2, line 66 - column 3, line 53 claims 1,9-12,14-16	1-37
A	EP 1 184 040 A (SURFACE CARE GMBH) 6 March 2002 (2002-03-06) claims 1-3,6 ----- -/--	1-37

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

10 September 2004

Date of mailing of the international search report

17.09.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Heck, G

INTERNATIONAL SEARCH REPORT

International Application No
IB 03/04506

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>US 4 845 038 A (BARR STEPHEN M ET AL) 4 July 1989 (1989-07-04) column 4, line 9 - line 34 claims 1-4</p>	38-42

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 03/04506

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 28-37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 28-37 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: -

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by surgery/therapy

INTERNATIONAL SEARCH REPORT

In International Application No

IB 03/04506

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0025838	A	11-05-2000	BE 1012536 A3 AU 763443 B2 AU 1467100 A CA 2348904 A1 DE 1124591 T1 EP 1124591 A1 JP 2002528233 T WO 0025838 A1	05-12-2000 24-07-2003 22-05-2000 11-05-2000 07-02-2002 22-08-2001 03-09-2002 11-05-2000
US 5474770	A	12-12-1995	FR 2639958 A1 AT 113071 T DE 68918922 D1 DE 68918922 T2 EP 0373044 A1 ES 2060803 T3	08-06-1990 15-11-1994 24-11-1994 20-04-1995 13-06-1990 01-12-1994
EP 1184040	A	06-03-2002	DE 10041468 C1 AT 252918 T DE 50100859 D1 EP 1184040 A1	07-03-2002 15-11-2003 04-12-2003 06-03-2002
US 4845038	A	04-07-1989	CA 1322149 C DE 3833086 A1 FR 2621048 A1 GB 2210385 A ,B JP 1128780 A US 4939152 A US 5462875 A US 5071766 A	14-09-1993 13-04-1989 31-03-1989 07-06-1989 22-05-1989 03-07-1990 31-10-1995 10-12-1991